Enveric Biosciences (NASDAQ:ENVB) CEO David Johnson talks to Proactive about how the group has 'multiple shots on goal' with its current pipeline that aims to use CBD to treat a variety of indications. Johnson says most recently, it acquired an exclusive license for five molecules from Diverse Biotech to help alleviate the side effects that cancer patients experience.
Enveric Biosciences CEO describes how the group has 'multiple shots on goal' with current pipeline
